FDA Expands Indication for CrossBoss, Stingray to Treat CTOs
CTOs are chronically stenosed lesions that completely block a coronary artery – typically for three months or longer – and prevent blood circulation to critical areas of the heart.
This expanded indication is the result of data generated from the 147-patient FAST-CTOs clinical trial in which the safety and effectiveness of the system in coronary chronic total occlusions was demonstrated.
The FDA granted the expanded indication in May 2011.
For more information: www.bridgepointmedical.com